Six months of prevention -- that's how long Lenacapavir, the new drug for HIV prevention lasts.The Food and Drug Administration approved it last month, and desp ...

Lenacapavir is available in both oral tablet form and as subcutaneous injections. It is available as oral tablets and ...

If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

Note that some links may require registration or subscription. The Department of Justice said it sent more than 20 subpoenas to doctors and clinics involved with transgender medical procedures on ...

Gilead Sciences is pushing full speed ahead with its strategy to ensure global access to its long-acting HIV pre-exposure ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...

Lenacapavir, the first FDA-approved, twice-yearly injectable PrEP for HIV prevention, shows 96% efficacy and offers ...

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...